Our proprietary technology platform systematically leverages the powerful tools of big genomic data and AI to build molecular networks: a set of interconnected potential therapeutic targets.
Harnessing disease molecular networks, we screen both generic compounds and NCEs to develop novel drug combinations hitting multiple highly relevant disease targets.
Formulated with optimal doses of their components, our products are expected to be safer and more effective than existing therapies.
Find the full recording of Pharnext’s virtual R&D Day: unmet need in Charcot-Marie-Tooth Disease Type 1A, potential for PXT3003, interest of our Pleotherapy platform.
Pharnext will attend joint meeting of the Associazione Italiana per lo studio del Sistema Nervoso Periferico and the Associazione Italiana di Miologia